# Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor

> **NCT03518138** · PHASE2 · COMPLETED · sponsor: **Que Oncology** · enrollment: 132 (actual)

## Conditions studied

- Vasomotor Symptoms (VMS)

## Interventions

- **DRUG:** Q-122
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03518138
- **Lead sponsor:** Que Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-10-24
- **Primary completion:** 2020-07-29
- **Final completion:** 2020-09-09
- **Target enrollment:** 132 (ACTUAL)
- **Last updated:** 2021-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03518138

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03518138, "Safety/Efficacy of Q-122 in Breast Cancer Patients Taking Tamoxifen or Aromatase Inhibitor". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03518138. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*